CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) — Company COO Dr. Pañeda will discuss SemaPhoreTM…
Proceeds expected to extend cash runway to fund operations into the second half of 2024…
Topline data expected in the first half of 2023 SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE…
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Lake Street Capital Markets LLC engaged to act as an advisor to the Company Board…
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with…
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the…
VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Jan. 10, 2023 (GLOBE NEWSWIRE) — Atlas…
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10,…
Live video webcast on Wednesday, January 18th at 3:00 PM ET EDMONTON, Alberta, Jan. 10,…
Proprietary AMPS platform enables the systematic and rapid interrogation of protein-metabolite interactions to reveal new,…
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late-…
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to…
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO),…
REDWOOD CITY, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”…
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected…
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023 Progress preclinical research…